XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

AUGUST 9, 2022

Innova Medical Group, the world’s largest COVID-19 test provider, has secured the licensing rights for commercializing a new COVID-19 testing technology developed at the University of Birmingham. Innova Medical Group, which secured the licensing rights for the test, is the world’s largest provider of lateral flow tests.

Licensing 98

Licensing Licensing DNA RNA 98

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. “We

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

pharmaphorum

DECEMBER 13, 2021

In November, it signed a licensing deal with Chinese tech giant Baidu to partner on its artificial intelligence platform, which has been developed specifically to optimise mRNA sequences for mRNA-based therapeutics. Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years.

RNA 105

RNA Vaccination Vaccine Development 105

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Ribometrix has presented that many RNAs implicated in disease comprise structural pockets amenable to targeting with small molecules.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

pharmaphorum

JUNE 1, 2022

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk factor for cardiovascular disease – that was sustained over 48 weeks of follow-up.

Gene Silencing 59

Gene Silencing Drugs Medicine RNA 59

pharmaphorum

NOVEMBER 24, 2020

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran) was also approved in the European Union last week, making it the third from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

FDA Approval 52

FDA Approval Gene Silencing Drugs RNA 52

Delveinsight

AUGUST 5, 2021

Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acquire a research partner Translate Bio for USD 3.2 Sanofi bets USD 3.2 No financial terms were revealed.

Vaccination 98

Vaccination Vaccine Gene Therapy Development 98

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Protein 52

Protein RNA Production Genetics 52

The Pharma Data

DECEMBER 8, 2020

The assumption is SciNeuro will start with Parkinson’s disease and pain in addition to rare genetic diseases, after scaling up staffing. . Laying down a new track for RNA processing, Remix launched with $81 million in financing. The impact of CNS diseases extends beyond patients—to their families and society as well.”

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs.

Genetic Disease 52

Genetic Disease Antibody Licensing Licensing 52

pharmaphorum

NOVEMBER 23, 2021

The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 million in milestones – covers rights to ARO-HSD, Arrowhead’s RNA interference drug targeting an enzyme called HSD17B13 that seems to contribute to the pathology of NASH and other liver diseases.

Sales 52

Sales Drugs Trials RNA 52

The Pharma Data

JANUARY 21, 2021

In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50

FDA Approval 52

FDA Approval RNA Drugs Containment 52

The Pharma Data

AUGUST 30, 2021

As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Leqvio is the first and only approved small interfering RNA (siRNA) LDL-C-lowering treatment in Europe 6,7. It is currently under review by the U.S. a statin or ezetimibe).

RNA 52

RNA Trials Production Containment 52

The Pharma Data

MARCH 4, 2021

Dravet syndrome is most commonly caused by a genetic mutation in the SCN1A gene and affects approximately 1 in 15,000 to 1 in 21,000 people in the United States. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI).

Development 52

Development Containment Medicine Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. For more information, visit www.merck.com and connect with us on Twitter , Facebook , Instagram , YouTube and LinkedIn. For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. For more information, visit. www.merck.com. and connect with us on. For more information, visit. www.novavax.com. and connect with us on.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

FDA Law Blog

OCTOBER 24, 2024

In 2010, the Association for Molecular Pathology (AMP), among other organizations, brought suit against Myriad Genetics, challenging the validity of the company’s patents on the BRCA 1/2 genes. animal, viral, bacterial) DNA and RNA sequences. Supporters of AMP v.

Gene 64

Gene DNA Genetics Gene Sequencing 64

XTalks

FEBRUARY 20, 2025

In hereditary angioedema (HAE), for example, donidalorsen an investigational RNA-targeted prophylactic treatment has demonstrated impressive efficacy. The FDA has accepted a Biologics License Application (BLA) and designated Priority Review to UX111, offering a potential option for affected families.

Gene Therapy 59

Gene Therapy Gene Research Genetics 59